Clinical Trial Using Humira in Netherton Syndrome

• Status: Completed
• Trial end date: 2017-09-21
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this studies therapeutic : to determine the effect of Adalimumab (HumiraR) on clinical inflammatory manifestations of patients with Netherton syndrome after 3 months of treatment , with a post treatment period follow-up of 3 months.

Second objectives are To evaluate the safety of Adalimumab in the context of NS To evaluate the improvement of the quality of life at 3 months To evaluate the improvement of pruritus and pain in the patients To study markers of inflammatory and allergy in NS prior and after treatment Benefit of the study An improvement by at least 20% of the cutaneous signs in these patients who suffer from a genetic incurable, chronic, painful and very afflicting disease would be of a great help for these patients. NS is a major source of social exclusion.

Risks They are inherent to the risks of biotherapies, especially for an anti-TNF therapy, they comprise a risk of infection. Cutaneous infections occur mainly during infancy, and we have therefore chosen to treat patients over 4 years of age in this study.

A close clinical surveillance will be set up (initially every week during the first month of treatment, then every month). This will represents a large number of visits but will provide a high level of security.

Benefits/risks ratio In the absence of curative treatment for these patients with a severe genetic skin disease, the benefits/risks ration clearly appears to be in favour of an expected benefit.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Adalimumab

Criteria

Inclusion Criteria:

• Patient over 4 years of age at the time of enrolment

• Patient with a clinical, immuno-histochemical and/or molecular diagnosis confirmed

• Vaccinations to date

• Informed consent form signed by the patient and/or his parents (or the legal authority) if the patient is a child

• Patient with social security coverage

Exclusion Criteria:

• Ongoing severe infections

• Well known allergy to one of Adalimumab ingredients

• Allergy to xylocaine

• Ongoing treatment to immunosuppressive drugs and biotherapies

• History of malignancy

• Heart, renal, haematological and/or confirmed hepatic involvement

• Pregnant, or breastfeeding, patients

• Anomalies of the standard balance sheet: neutropenia < 1000/mm3, polynucleose > 12 000 / mm3 - lymphopenia < 1000 / mm3 - anemia < 9g / 100ml - thrombocytopenia < 150 000 /mm3, thrombocytosis > 500 000/mm3 - transaminase > 3N